Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source outlines the potential effects of treatments commonly used in trichology on SARS-CoV-2 infection and offers a guide for managing trichological patients during the COVID-19 era, addressing the challenges of safely visiting and treating patients.

This study identified various methodological inconsistencies in systematic reviews on platelet-rich plasma therapy for pattern hair loss, suggesting a need for rigorous adherence to established guidelines.

This article reviews two new legislative measures affecting domiciliary care workers in Wales and reports no new research results; it highlights implications for labor law and devolution debates.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.

This chapter reviews the epidemiology, clinical manifestations, diagnosis, treatment, and outcomes of severe acute respiratory syndrome (SARS) in children, but presents no new clinical results.

This study found a statistically significant increase in glycosylated hemoglobins among patients with adult-acquired panhypopituitarism undergoing long-term GH replacement therapy, with two developing diabetes requiring treatment.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

This correspondence explores potential links between SARS-CoV-2 and androgenic alopecia, reporting no new clinical findings and suggesting a need for further investigative studies.

In this study, patients with advanced androgenetic alopecia stages had higher carotid intima media thickness and worse aortic elasticity, suggesting a potential link to subclinical atherosclerosis.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This creative piece by Christa Fairbrother poetically explores the experiences of living with arthritis, with no new research findings reported.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This review highlights the mixed roles of testosterone in COVID-19, noting both potential benefits through anti-inflammatory effects and risks due to increased virus entry, with low testosterone linked to increased severity.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.